You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

Cardioprevention Post-COVID-19

  • Authors: Deepak Bhatt, MD, MPH; Charles Vega, MD, FAAFP; Karol Watson, MD, PhD
  • CME / CE Released: 2/24/2022
  • Valid for credit through: 2/24/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    Nurses - 0.50 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)

    Pharmacists - 0.50 Knowledge-based ACPE (0.050 CEUs)

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for a healthcare provider (HCP) audience of primary care/internal medicine physicians (PCPs), cardiologists, neurologists/neurosurgeons, nurses, nurse practitioners (NPs), physician assistants (PAs), and pharmacists.

The goal of this activity is to increase physicians’ knowledge regarding aspirin for cardioprevention and to improve their competence related to communication strategies to improve shared decision-making and adherence through the use of telemedicine.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Strategies to use telehealth which can improve access to aspirin therapy for primary prevention
  • Have greater competence related to
    • HCP-patient communication strategies to improve shared decision-making related to appropriate use of antiplatelet therapy for primary prevention
    • Effective strategies to use telehealth to improve adherence to aspirin therapy in the setting of primary prevention


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.

-


Faculty

  • Deepak Bhatt, MD, MPH

    Professor of Medicine
    Harvard Medical School
    Executive Director, Interventional Cardiovascular Programs
    Brigham and Women's Hospital Heart & Vascular Center
    Boston, Massachusetts

    Disclosures

    Grants for clinical research from: Abbott; Afimmune; Amarin; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cardax; CellProthera; Cereno Scientific; Chiesi; CSL Behring; Eisai; Ethicon; Ferring Pharmaceuticals; Forest Laboratories; Fractyl; Garmin; HLS Therapeutics; Idorsia; Ironwood; Ischemix; Janssen; Lexicon; Lilly; Medtronic; MyoKardia; NirvaMed; Novartis; Novo Nordisk; Owkin; Pfizer; PhaseBio; PLx Pharma; Regeneron; Roche; Sanofi; Synaptic; The Medicines Company; 89Bio
    Advisor or consultant for: Abbott; Afimmune; Amarin; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cardax; CellProthera; Cereno Scientific; Chiesi; CSL Behring; Eisai; Ethicon; Ferring Pharmaceuticals; Forest Laboratories; Fractyl; Garmin; HLS Therapeutics; Idorsia; Ironwood; Ischemix; Janssen; Lexicon; Lilly; Medtronic; MyoKardia; NirvaMed; Novartis; Novo Nordisk; Owkin; Pfizer; PhaseBio; PLx Pharma; Regeneron; Roche; Sanofi; Synaptic; The Medicines Company; 89Bio

  • Charles Vega, MD, FAAFP

    Clinical Professor, Family Medicine
    Assistant Dean, University of California-Irvine School of Medicine
    Director, UC Irvine Program in Medical Education for the Latino Community (PRIME-LC)
    Irvine, California

    Disclosures

    Advisor or consultant for: Johnson & Johnson

  • Karol Watson, MD, PhD

    Professor of Medicine/Cardiology
    David Geffen School of Medicine at UCLA
    University of California – Los Angeles
    Los Angeles, California

    Disclosures

    Advisor or consultant for: Amarin; Amgen; Boehringer Ingelheim; Esperion; Lilly; Novartis
    Speaker or member of speakers bureau for: Boehringer Ingelheim; Lilly

Steering Committee

  • Charles P. Vega, MD, FAAFP


    As Seen Above

  • Fuad M. Baroody, MD

    Professor of Otolaryngology-Head and Neck Surgery and Pediatrics
    The University of Chicago Medicine
    Comer Children's Hospital
    Chicago, Illinois

    Disclosures

    Disclosure: Fuad M. Baroody, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ALK; AstraZeneca; Bayer; GlaxoSmithKline; Regeneron; Sanofi

  • Deepak L. Bhatt, MD, MPH

    As Seen Above

  • Stephen Brunton, MD, FAAFP

    Executive Vice President
    Primary Care Education Consortium
    Murrieta, California

    Disclosures

    Disclosure: Stephen Brunton, MD, FAAFP, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Abbott Diabetes; Bayer Diabetes; Gelesis; Novo Nordisk; Sanofi Aventis
    Served as a speaker or a member of a speakers bureau for: AstraZeneca; Bayer Diabetes; Boehringer Ingelheim; Lilly; Novo Nordisk
    Owns stock, stock options, or bonds from: Paracrine Cell Therapy

  • Linda Cox, MD

    Practicing Physician
    Allergy and Asthma Center
    Ft. Lauderdale, Florida

    Disclosures

    Disclosure: Linda Cox, MD, has disclosed no relevant financial relationships.

  • Roxana Mehran, MD

    Professor of Medicine
    Director
    Interventional Cardiovascular Research and Clinical Trials
    Icahn School of Medicine at Mount Sinai
    New York, New York

    Disclosures

    Disclosure: Roxana Mehran, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ACC; Cine-Med Research; CIRM; Janssen; SCAI; WebMD
    Received grants for clinical research from: Abbott; Abiomed; Applied Therapeutics; Arena; AstraZeneca; Bayer; Biosensors; Bristol Myers Squibb; BSC; CardiaWave; CellAegis; CERC; Chiesi; Concept Medical; CSL Behring; DSI; Insel Gruppe AG; Medtronic; Novartis; OrbusNeich; Philips; Transverse Medical; Zoll

Editor

  • Clinton W. Wright, PharmD, BCPP

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Clinton W. Wright, PharmD, BCPP, has disclosed no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer-reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.50 contact hour(s) ( 0.050 CEUs) (Universal Activity Number: JA0007105-0000-22-044-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

Cardioprevention Post-COVID-19

Authors: Deepak Bhatt, MD, MPH; Charles Vega, MD, FAAFP; Karol Watson, MD, PhDFaculty and Disclosures

CME / CE Released: 2/24/2022

Valid for credit through: 2/24/2023

processing....

Select Any Chapter to Begin

Note: The information on the coronavirus outbreak is continually evolving. The content within this activity serves as a historical reference to the information that was available at the time of this publication. We continue to add to the collection of activities on this subject as new information becomes available. It is the policy of Medscape Education to avoid the mention of brand names or specific manufacturers in accredited educational activities. However, manufacturer names related to the approved COVID-19 vaccines are provided in this activity in an effort to promote clarity. The use of manufacturer names should not be viewed as an endorsement by Medscape of any specific product or manufacturer.  

Did you know that there are digital solutions that may help your patients with adherence to aspirin for primary prevention of CVD?